Literature DB >> 25573971

Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.

Betty Lamothe1, Fabiola Cervantes-Gomez1, Mariela Sivina2, William G Wierda2, Michael J Keating2, Varsha Gandhi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25573971      PMCID： PMC4287645          DOI： 10.1182/blood-2014-07-585364

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

Review 1.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

Review 2.  Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress.

Authors:  Ira Tabas; David Ron
Journal:  Nat Cell Biol       Date:  2011-03       Impact factor: 28.824

3.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors:  Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

4.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.

Authors:  Maria Baou; Susan L Kohlhaas; Michael Butterworth; Meike Vogler; David Dinsdale; Renata Walewska; Aneela Majid; Eric Eldering; Martin J S Dyer; Gerald M Cohen
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

6.  Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation.

Authors:  Betty Lamothe; Arnaud Besse; Alejandro D Campos; William K Webster; Hao Wu; Bryant G Darnay
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

Review 7.  Carfilzomib.

Authors:  K Martin Kortuem; A Keith Stewart
Journal:  Blood       Date:  2013-02-07       Impact factor: 22.113

8.  The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.

Authors:  Sneha V Gupta; Erin Hertlein; Yanhui Lu; Ellen J Sass; Rosa Lapalombella; Timothy L Chen; Melanie E Davis; Jennifer A Woyach; Amy Lehman; David Jarjoura; John C Byrd; David M Lucas
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

Authors:  S E M Herman; C U Niemann; M Farooqui; J Jones; R Z Mustafa; A Lipsky; N Saba; S Martyr; S Soto; J Valdez; J A Gyamfi; I Maric; K R Calvo; L B Pedersen; C H Geisler; D Liu; G E Marti; G Aue; A Wiestner
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528
View more
  13 in total

1.  Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.

Authors:  Adam A Friedman; Yun Xia; Lorenzo Trippa; Long Phi Le; Vivien Igras; Dennie T Frederick; Jennifer A Wargo; Kenneth K Tanabe; Donald P Lawrence; Donna S Neuberg; Keith T Flaherty; David E Fisher
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

2.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Fabiola Cervantes-Gomez; Betty Lamothe; Jennifer A Woyach; William G Wierda; Michael J Keating; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 3.  Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.

Authors:  Joseph Maly; James S Blachly
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

4.  Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.

Authors:  Yaya Chu; Sanghoon Lee; Tishi Shah; Changhong Yin; Matthew Barth; Rodney R Miles; Janet Ayello; Erin Morris; Lauren Harrison; Carmella Van de Ven; Paul Galardy; Stanton C Goldman; Megan S Lim; Michelle Hermiston; Linda M McAllister-Lucas; Lisa Giulino-Roth; Sherrie L Perkins; Mitchell S Cairo
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

5.  Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.

Authors:  Betty Lamothe; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

6.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

7.  Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Authors:  Viralkumar Patel; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2015-11-16

Review 8.  Precision medicine for cancer with next-generation functional diagnostics.

Authors:  Adam A Friedman; Anthony Letai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Cancer       Date:  2015-11-05       Impact factor: 60.716

9.  Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.

Authors:  Christian Schmidl; Gregory I Vladimer; André F Rendeiro; Susanne Schnabl; Thomas Krausgruber; Christina Taubert; Nikolaus Krall; Tea Pemovska; Mohammad Araghi; Berend Snijder; Rainer Hubmann; Anna Ringler; Kathrin Runggatscher; Dita Demirtas; Oscar Lopez de la Fuente; Martin Hilgarth; Cathrin Skrabs; Edit Porpaczy; Michaela Gruber; Gregor Hoermann; Stefan Kubicek; Philipp B Staber; Medhat Shehata; Giulio Superti-Furga; Ulrich Jäger; Christoph Bock
Journal:  Nat Chem Biol       Date:  2019-01-28       Impact factor: 15.040

10.  The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Authors:  Johannes Kraus; Marianne Kraus; Nora Liu; Lenka Besse; Jürgen Bader; Paul P Geurink; Gerjan de Bruin; Alexei F Kisselev; Herman Overkleeft; Christoph Driessen
Journal:  Cancer Chemother Pharmacol       Date:  2015-06-23       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.